- Home
- BEAM vs JBLU Comparison
BEAM vs JBLU Comparison
Compare BEAM & JBLU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- JBLU
- Stock Information
- Founded
- BEAM 2017
- JBLU 1998
- Country
- BEAM United States
- JBLU United States
- Employees
- BEAM N/A
- JBLU N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- JBLU Air Freight/Delivery Services
- Sector
- BEAM Health Care
- JBLU Consumer Discretionary
- Exchange
- BEAM Nasdaq
- JBLU Nasdaq
- Market Cap
- BEAM 1.8B
- JBLU 2.1B
- IPO Year
- BEAM 2020
- JBLU N/A
- Fundamental
- Price
- BEAM $17.00
- JBLU $3.67
- Analyst Decision
- BEAM Strong Buy
- JBLU Sell
- Analyst Count
- BEAM 11
- JBLU 12
- Target Price
- BEAM $50.50
- JBLU $5.00
- AVG Volume (30 Days)
- BEAM 3.0M
- JBLU 30.6M
- Earning Date
- BEAM 05-06-2025
- JBLU 04-22-2025
- Dividend Yield
- BEAM N/A
- JBLU N/A
- EPS Growth
- BEAM N/A
- JBLU N/A
- EPS
- BEAM N/A
- JBLU N/A
- Revenue
- BEAM $63,518,000.00
- JBLU $9,279,000,000.00
- Revenue This Year
- BEAM N/A
- JBLU $6.12
- Revenue Next Year
- BEAM $6.32
- JBLU $6.33
- P/E Ratio
- BEAM N/A
- JBLU N/A
- Revenue Growth
- BEAM N/A
- JBLU N/A
- 52 Week Low
- BEAM $13.53
- JBLU $3.34
- 52 Week High
- BEAM $35.25
- JBLU $8.31
- Technical
- Relative Strength Index (RSI)
- BEAM 40.71
- JBLU 35.05
- Support Level
- BEAM $16.04
- JBLU $3.34
- Resistance Level
- BEAM $17.94
- JBLU $3.81
- Average True Range (ATR)
- BEAM 1.84
- JBLU 0.43
- MACD
- BEAM 0.26
- JBLU -0.03
- Stochastic Oscillator
- BEAM 44.24
- JBLU 19.08
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About JBLU JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The operating segments of company are Domestic & Canada, Caribbean & Latin America and Atlantic. Majority of revenue is generated from Domestic & Canada segment.